COCP Latest Press Releases

-- April 2, 2026 --

Cocrystal Pharma Receives FDA Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Preventive Globe Newswire 8:00 AM

-- March 31, 2026 --

Cocrystal Pharma Reports 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs Globe Newswire 8:00 AM

-- March 9, 2026 --

First Subjects Dosed in Cocrystal Pharma's Phase 1b Study Evaluating CDI-988 for Norovirus Prevention and Treatment Globe Newswire 8:00 AM

-- February 19, 2026 --

Cocrystal Pharma's First Oral Norovirus Protease Inhibitor CDI-988 to be Featured at the International Society for Antiviral Research Conference (ICAR) 2026 Globe Newswire 8:00 AM

-- December 18, 2025 --

Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus Globe Newswire 8:00 AM

-- December 1, 2025 --

Cocrystal Pharma to Present at the Noble Capital Markets' 21st Emerging Growth Equity Conference Globe Newswire 8:00 AM

-- November 14, 2025 --

Cocrystal Pharma Reports Third Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs Globe Newswire 8:00 AM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software